| Literature DB >> 10639370 |
P Clayette1, M Martin, V Beringue, N Dereuddre-Bosquet, K T Adjou, M Seman, D Dormont.
Abstract
Amphotericin B derivatives, such as MS-8209, have been evaluated as a therapeutic approach to human immunodeficiency virus (HIV) infection. We show that MS-8209, like amphotericin B, increases tumor necrosis factor alpha (TNF-alpha) mRNA expression and TNF-alpha production and consequently HIV replication in human macrophages. These effects confirm the pharmacological risk associated with the administration of amphotericin B or its derivatives to HIV-infected patients.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10639370 PMCID: PMC89691 DOI: 10.1128/AAC.44.2.405-407.2000
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191